Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Greenwich Lifescienses, Inc. is a biopharmaceutical company developing immunotherapies targeting HER2/neu-expressing cancers, primarily breast cancer. Its lead candidate, GLSI-100 (GP2 + GM-CSF), aims to prevent cancer recurrence through clinical-stage trials, including Phase III. The company focuses on cancer immunotherapy, leveraging immune system activation, with plans for global commercialization and strategic partnerships in oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.